Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22627228 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1HTR2CMEN1 | |
| SCHEMBL21397345 | 0.91 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1HTR2CMEN1 | |
| SCHEMBL24943926 | 0.81 | KDM4E (0.50) | ALDH1A1MAPK1L3MBTL1HTR2CMEN1 | |
| SCHEMBL23027037 | 0.81 | LTA4H (0.48) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL22280532 | 0.81 | LTA4H (0.48) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL2378732 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1HTR2CMEN1KMT2ACYP2C19 | |
| SCHEMBL23186133 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1HTR2CMEN1KMT2ACYP2C19 | |
| SCHEMBL13330343 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1HTR2CMEN1KMT2ACYP2C19 | |
| SCHEMBL2379232 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1HTR2CMEN1KMT2ACYP2C19 | |
| SCHEMBL28429589 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1HTR2CMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 1556/4885MAPK1 139/4885L3MBTL1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.